BridgeMD
New treatment option for Specific Language and Learning Disorders (SLLD)
Official title Study of the Value of Trio Exome Sequencing in the Etiological Assessment of Specific Non-syndromic Language and Learning Disorders
ClinicalTrials.gov ID: NCT05939739
What this study is testing
What is Blood samples?
Blood samples is an investigational medicine, being studied as a potential treatment for specific language and learning disorders (slld).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Specific language and learning disorders (SLLD) affect around 5-10% of school-aged children, or 1-2 child(ren) per class. SLLDs correspond to the impairment of a specific cognitive function and are divided into 5 categories: dyslexia, dysphasia, dyspraxia, dyscalculia and attention deficit hyperactivity disorder (ADHD) (DSM-5).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 3 to 40
You may be able to join if
- Index case suffering from one or more severe learning disorders (requiring in-school help or intensive rehabilitation), justified by...
- Index case aged 3 to 40 years
- Sample may be taken from index case and 2 known biological parents
- Consent signed by the parents and by the index case if major
- Index case and parents covered by national health insurance
You likely can't join if
- Index case and parents have a condition which, in the opinion of the investigator, would contraindicate the subject's participation in the study.
- Intellectual disability confirmed by neuropsychological testing or strongly suspected clinically in the index case and/or his/her parents
- Obvious syndromic diagnosis (syndrome or antecedents having definitely led to a developmental disorder)
- Persons deprived of liberty by judicial or administrative decision,
- Adults under guardianship,
- Persons residing in a health or social establishment
See the full eligibility criteria
- Index case suffering from one or more severe learning disorders (requiring in-school help or intensive rehabilitation), justified by neuropsychological and/or speech therapy and/or occupational therapy assessments...
- Index case aged 3 to 40 years
- Sample may be taken from index case and 2 known biological parents
- Consent signed by the parents and by the index case if major
- Index case and parents covered by national health insurance
- Index case and parents have a condition which, in the opinion of the investigator, would contraindicate the subject's participation in the study.
- Intellectual disability confirmed by neuropsychological testing or strongly suspected clinically in the index case and/or his/her parents
- Obvious syndromic diagnosis (syndrome or antecedents having definitely led to a developmental disorder)
- Persons deprived of liberty by judicial or administrative decision,
- Adults under guardianship,
- Persons residing in a health or social establishment
- Patients in critical situations
- Pregnant, parturient or nursing women
- Previous array CGH and/or Fragile X testing or any other targeted genetic examination (except standard karyotype).
The study team makes the final eligibility decision.
Where it's taking place
- Dijon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 3 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dijon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.